Hypertension – Current Treatment – Detailed, Expanded Analysis: Hyperaldosteronism: Treatment Algorithms: Claims Data Analysis (US)
Market Outlook
Hyperaldosteronism is characterized by the excessive release of aldosterone hormone into the blood and the resulting rise in blood pressure. This disorder is a common cause of secondary hypertension, and often patients are initially misdiagnosed as hypertensive. The cause of hyperaldosteronism is the key factor for determining the treatment approach. Surgical treatment is an option for primary hyperaldosteronism. Where surgical excision is not appropriate or needs to be supplemented, pharmacotherapy is indicated and a polypharmacy treatment approach is frequently adopted. Numerous drug treatments are available, including aldosterone antagonists, renin-angiotensin-aldosterone system (RAAS) inhibitors, calcium channel blockers, and beta blockers. The hyperaldosteronism Treatment Algorithm provides insights into prescribing patterns among many treatment options.
Questions Answered
- What patient shares do key therapy drug classes garner by line of therapy in newly diagnosed hyperaldosteronism patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed hyperaldosteronism patients?
- How are aldosterone antagonists integrated into the treatment algorithm?
- What proportion of hyperaldosteronism patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of hyperaldosteronism patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the compliance and persistency rates among drug-treated patients with hyperaldosteronism?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Key drugs: angiotensin-converting enzyme inhibitors, aldosterone antagonists, angiotensin II receptor blockers, adrenergic receptor blockers, calcium channel blockers, diuretics, direct renin inhibitors, corticosteroids.
Key analysis provided:
- Brand usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flow charts.
Table of contents
- Hypertension - Current Treatment - Detailed, Expanded Analysis: Hyperaldosteronism: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms Claims Data Analysis in Hyperaldosteronism - Data Output File [August 2018]
- Treatment Algorithms - Claims Data Analysis - Hyperaldosteronism - PPT [August 2018]
- Introduction to Current Treatment for Hyperaldosteronism
- Please Note:
- Key Findings
- Summary Figures
- Introduction to Current Treatment and Medical Practice for Hyperaldosteronism
- Background
- Drugs Included in This Study of Current Treatment for Hyperaldosteronism
- Patient Selection Criteria for Hyperaldosteronism
- Diagnosis Codes Used for Patient Selection
- Query 1: Newly Diagnosed Patients: A Prospective Analysis of Treatment Flow Following First Diagnosis
- Query 2: Recently Treated Patients: A Retrospective Analysis of Treatment Progression Among All Drug-Treated Patients
- Query 3: Persistency: A One-Year Measurement of Persistence Among Drug-Treated Patients Not Limited to New-to-Brand
- Query 4: Compliance: A Six-Month Measurement of Drug Compliance Among Fully Persistent Patients
- Executive Summary
- Appendix: Methodology
- Key Abbreviations
- Data Sources of Longitudinal Patient-Level Claims Data
- Data Flow for Longitudinal Patient-Level Claims Data
- Methodology for Newly Diagnosed Patient Analysis
- Timeline for Newly Diagnosed Patient Analysis
- Methodology for Recently Treated Patient Analysis
- Timeline for Recently Treated Patient Analysis
- Methodology for Persistency Analysis
- Patients Included in Persistency Analysis
- Methodology for Compliance Analysis
- Patients Included in Compliance Analysis
Rameshwar Prajapati, M.S.(Pharm.), Ph.D., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He focuses on the treatment of obesity and peripheral arterial disease but has also authored content on other cardiovascular, renal, and metabolic indications. Dr. Prajapati earned a bachelor’s degree in pharmacy from Hari Singh Gour University and a master’s degree and Ph.D. in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S. Nagar India.